GGYPX
Price
$16.45
Change
-$0.03 (-0.18%)
Updated
Sep 20 closing price
VFIAX
Price
$527.71
Change
-$1.02 (-0.19%)
Updated
Sep 20 closing price
Ad is loading...

GGYPX vs VFIAX

Header iconGGYPX vs VFIAX Comparison
Open Charts GGYPX vs VFIAXBanner chart's image
Goldman Sachs Focused Value P
Price$16.45
Change-$0.03 (-0.18%)
VolumeN/A
CapitalizationN/A
Vanguard 500 Index Admiral
Price$527.71
Change-$1.02 (-0.19%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
GGYPX vs VFIAX Comparison Chart
Loading...
VS
GGYPX vs. VFIAX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GGYPX is a StrongBuy and VFIAX is a Buy.

FUNDAMENTALS
Fundamentals
VFIAX has more cash in the bank: 1.24T vs. GGYPX (57.6M). VFIAX (1.32) and GGYPX (1.29) have matching dividends . GGYPX was incepted earlier than VFIAX: GGYPX (6 years) vs VFIAX (24 years). GGYPX is a more actively managed with annual turnover of: 82.00 vs. VFIAX (2.00). GGYPX has a lower initial minimum investment than VFIAX: GGYPX (0) vs VFIAX (3000). VFIAX annual gain was more profitable for investors over the last year : 31.72 vs. GGYPX (27.83). VFIAX return over 5 years is better than : 90.47 vs. GGYPX (55.04).
GGYPXVFIAXGGYPX / VFIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence6 years24 years-
Gain YTD16.71419.97184%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets57.6M1.24T0%
Annual Yield % from dividends1.291.3298%
Returns for 1 year27.8331.7288%
Returns for 3 years20.4030.9966%
Returns for 5 years55.0490.4761%
Returns for 10 yearsN/A190.48-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BLBD54.491.17
+2.19%
Blue Bird Corp
MPLX44.200.07
+0.16%
Mplx LP
AIP7.45-0.08
-1.06%
Arteris
FFIN38.10-0.74
-1.91%
First Financial Bankshares
TPST1.35-0.06
-4.26%
Tempest Therapeutics